Tumors Detection Solution

With its high sensitivity and specificity, digital PCR has demonstrated significant value in liquid biopsy for cancer management throughout the entire cancer care continuum, including early cancer screening, diagnosis, prognosis, personalized treatment, and monitoring of disease progression.Tumor heterogeneity refers to the different molecular biological characteristics of cells within the same type of tumor, which can be spatial or temporal heterogeneity. Due to the presence of tumor heterogeneity, tissue biopsy can only reflect the situation at a certain time point and can not fully demonstrate the mutation panorama of the tumor. This not only affects diagnosis but also has an impact on treatment, therapeutic effect and disease monitoring, drug resistance, and prognosis. However, liquid biopsy can effectively avoid tumor heterogeneity. In addition, tissue biopsy is not able to be repeated at different times, but blood draw-based liquid biopsy is simple and can be carried out for timely detection. Through real-time monitoring, a major advantage of liquid biopsy is that the微量 circulating tumor DNA (ctDNA) in blood can provide tumor heterogeneity information and reflect dynamic changes in tumor burden. Therefore, as a non-invasive molecular detection method, liquid biopsy has gradually become an accurate and reliable alternative method for monitoring cancer. However, due to the significant challenges in detecting genomic abnormalities with very low abundance, there is a need to continue to improve liquid biopsy technology to meet daily clinical testing requirements. Digital PCR, as a highly sensitive and specific molecular detection method, can solve this technical problem. As a non-invasive molecular detection technology, liquid biopsy can overcome the limitations of tumor tissue detection and more accurately monitor tumor status. The samples of liquid biopsy mainly come from blood, but they can also come from other body fluids such as saliva, cerebrospinal fluid, feces, urine, etc. It is possible to isolate multiple tumor biomarkers from blood, such as circulating tumor cells (CTCs), exosomes (EVs), circulating free DNA (cfDNA), microRNA (miRNA), etc. The progress and standardization of molecular detection technology have made cfDNA detection develop rapidly. cfDNA is mainly composed of DNA secreted by a large number of normal cells and a small amount of DNA derived from tumor cells (ctDNA), therefore it is necessary to use highly sensitive molecular detection technology to accurately analyze genomic mutations in small amounts of ctDNA. With its high sensitivity and specificity, digital PCR has demonstrated significant value in liquid biopsy, participating in the entire cycle of cancer diagnosis and treatment management, including cancer diagnosis, prognosis, individualized treatment and monitoring disease progression.